LaFleur & Godfrey LLC Lowers Position in IDEXX Laboratories, Inc. $IDXX

Key Points

• LaFleur & Godfrey LLC reduced its holdings in IDEXX Laboratories by 4.6%, selling 478 shares and leaving them with 9,816 shares valued at approximately $5.27 million.
• IDEXX Laboratories' stock had a 12 month trading range of $356.14 to $688.12, closing at $656.16, while boasting a market capitalization of $52.49 billion.
• Several analysts have recently raised their price targets on IDEXX, with Morgan Stanley setting a new target of $765.00 and JPMorgan Chase increasing its target to $675.00.

LaFleur & Godfrey LLC reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 4.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,816 shares of the company's stock after selling 478 shares during the period. LaFleur & Godfrey LLC's holdings in IDEXX Laboratories were worth $5,265,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Mutual of America Capital Management LLC increased its stake in IDEXX Laboratories by 79.6% in the first quarter. Mutual of America Capital Management LLC now owns 19,430 shares of the company's stock valued at $8,160,000 after purchasing an additional 8,609 shares in the last quarter. Golden State Wealth Management LLC increased its stake in IDEXX Laboratories by 3,766.7% in the first quarter. Golden State Wealth Management LLC now owns 116 shares of the company's stock valued at $49,000 after purchasing an additional 113 shares in the last quarter. Sagespring Wealth Partners LLC bought a new stake in IDEXX Laboratories in the first quarter valued at $229,000. Plato Investment Management Ltd increased its stake in IDEXX Laboratories by 37.1% in the first quarter. Plato Investment Management Ltd now owns 3,087 shares of the company's stock valued at $1,310,000 after purchasing an additional 835 shares in the last quarter. Finally, Inspire Investing LLC increased its stake in IDEXX Laboratories by 34.4% in the first quarter. Inspire Investing LLC now owns 13,577 shares of the company's stock valued at $5,702,000 after purchasing an additional 3,472 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, Director M Anne Szostak sold 2,187 shares of the business's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the completion of the sale, the director directly owned 262 shares of the company's stock, valued at approximately $169,600.46. The trade was a 89.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Nimrata Hunt sold 1,200 shares of the stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $656.53, for a total transaction of $787,836.00. Following the transaction, the executive vice president owned 16,807 shares in the company, valued at approximately $11,034,299.71. The trade was a 6.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 54,057 shares of company stock valued at $34,293,468 in the last three months. Corporate insiders own 0.98% of the company's stock.

IDEXX Laboratories Stock Down 1.8%

NASDAQ:IDXX traded down $12.06 on Monday, reaching $644.10. 386,847 shares of the stock traded hands, compared to its average volume of 405,479. The company's fifty day simple moving average is $616.70 and its 200 day simple moving average is $523.10. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $51.53 billion, a price-to-earnings ratio of 53.63, a PEG ratio of 4.25 and a beta of 1.56. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.28 by $0.35. The firm had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business's quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter last year, the firm posted $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on IDXX shares. JPMorgan Chase & Co. lifted their price objective on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the company an "overweight" rating in a report on Monday, August 4th. Morgan Stanley boosted their target price on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the company an "overweight" rating in a research note on Friday, August 15th. Jefferies Financial Group assumed coverage on shares of IDEXX Laboratories in a research report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 price target on the stock. Stifel Nicolaus set a $640.00 target price on shares of IDEXX Laboratories in a report on Monday, August 4th. Finally, Leerink Partners upped their target price on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, IDEXX Laboratories currently has a consensus rating of "Moderate Buy" and a consensus target price of $649.44.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.